UB Paderborn / Katalog / Suche / in CDI

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

Cell, 2018-02, Vol.172 (4), p.825-840.e18

2018

Link zum Volltext

Verfügbarkeit prüfen

High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

Haematologica (Roma), 2009-12, Vol.94 (12), p.1669-1675

2009

Link zum Volltext

Verfügbarkeit prüfen

782-E Preliminary results of an in progress, first-in-human phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 2), p.A1815-A1815

2023

Link zum Volltext

Verfügbarkeit prüfen

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

The New England journal of medicine, 2012-03, Vol.366 (9), p.787-798

2012

Link zum Volltext

Verfügbarkeit prüfen

Treatment of chemotherapy-related anemia with erythropoietic agents: Current approaches and new paradigms

Seminars in hematology, 2004-10, Vol.41 (4 Suppl 7), p.9-16

Waltzman, Roger J.

2004

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-18-35: MT-5111, a novel HER2 targeting engineered toxin body, under clinical development to overcome mechanisms of resistance to existing HER2 targeted therapies

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-18-35

2020

Link zum Volltext

Verfügbarkeit prüfen

A randomized, active‐control, pilot trial of front‐loaded dosing regimens of darbepoetin‐alfa for the treatment of patients with anemia during chemotherapy for malignant disease

Cancer, 2004-04, Vol.100 (7), p.1545-1546

Waltzman, Roger J.

2004

Link zum Volltext

Verfügbarkeit prüfen

Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve

The oncologist (Dayton, Ohio), 2005-06, Vol.10 (6), p.438-448

2005

Link zum Volltext

Verfügbarkeit prüfen

MT-5111: A novel HER2 targeting engineered toxin body in clinical development

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.433-433

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS8074-TPS8074

2020

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 targeted engineered toxin body provides direct cytotoxicity and T-cell mediated tumor targeting

Journal of clinical oncology, 2020-02, Vol.38 (5_suppl), p.12-12

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of the novel immunotoxin, MT-5111, in subjects (subj) with HER-2 positive tumors: Interim results

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e15567-e15567

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2661: Engineered Toxin Bodies (ETBs): Clinical stage immunotoxins with a safer and differentiated profile

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2661-2661

2023

Link zum Volltext

Verfügbarkeit prüfen

In Reply

The oncologist (Dayton, Ohio), 2006-05, Vol.11 (5), p.536-537

Waltzman, Roger

2006

Link zum Volltext

Verfügbarkeit prüfen

In Reply

The oncologist (Dayton, Ohio), 2006-05, Vol.11 (5), p.536-537

Waltzman, Roger

2006

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-133: Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.LB-133-LB-133

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3095-3095

2018

Link zum Volltext

Verfügbarkeit prüfen

Invasive Anal Squamous-Cell Carcinoma in the HIV-Positive Patient: Outcome in the Era of Highly Active Antiretroviral Therapy

Diseases of the colon & rectum, 2008, Vol.51 (1), p.73-81

2008

Link zum Volltext

Verfügbarkeit prüfen

Abstract B001: A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B001-B001

2018

Link zum Volltext

Verfügbarkeit prüfen

A Pilot Study to Evaluate the Safety and Clinical Outcomes of Once-Weekly Epoetin Alfa 80,000 U in Anemic Patients with Cancer Receiving Chemotherapy

Supportive cancer therapy, 2005-10, Vol.3 (1), p.47-53

2005

Link zum Volltext

Verfügbarkeit prüfen

Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials

Haematologica (Roma), 2009-05, Vol.94 (5), p.743-744

2009

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of waterfall plots with the addition of nontarget lesion data

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.11082-11082

2013

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles

Blood, 2012-11, Vol.120 (21), p.3166-3166

2012

Link zum Volltext

Verfügbarkeit prüfen

Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 μg Every 2 Weeks) in Anemic Patients with Cancer Receiving Chemotherapy

The oncologist (Dayton, Ohio), 2005-09, Vol.10 (8), p.642-650

2005

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

782-E Preliminary results of an in progress, first-in-human phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Treatment of chemotherapy-related anemia with erythropoietic agents: Current approaches and new paradigms

Abstract P1-18-35: MT-5111, a novel HER2 targeting engineered toxin body, under clinical development to overcome mechanisms of resistance to existing HER2 targeted therapies

A randomized, active‐control, pilot trial of front‐loaded dosing regimens of darbepoetin‐alfa for the treatment of patients with anemia during chemotherapy for malignant disease

Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve

MT-5111: A novel HER2 targeting engineered toxin body in clinical development

A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma

PD-L1 targeted engineered toxin body provides direct cytotoxicity and T-cell mediated tumor targeting

A phase I study of the novel immunotoxin, MT-5111, in subjects (subj) with HER-2 positive tumors: Interim results

Abstract 2661: Engineered Toxin Bodies (ETBs): Clinical stage immunotoxins with a safer and differentiated profile

In Reply

In Reply

Abstract LB-133: Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors

Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies

Invasive Anal Squamous-Cell Carcinoma in the HIV-Positive Patient: Outcome in the Era of Highly Active Antiretroviral Therapy

Abstract B001: A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies

A Pilot Study to Evaluate the Safety and Clinical Outcomes of Once-Weekly Epoetin Alfa 80,000 U in Anemic Patients with Cancer Receiving Chemotherapy

Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials

Prognostic value of waterfall plots with the addition of nontarget lesion data

Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles

Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 μg Every 2 Weeks) in Anemic Patients with Cancer Receiving Chemotherapy

Suchergebnisse filtern